The sale is pre-planned under a 10b5-1 trading plan, reducing the likelihood of opportunistic insider selling. Monitor for any subsequent Form 4 filings to confirm execution and for any changes in insider selling patterns.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $164.85entry
- T+1 · 13d ago +0.73%α −0.92% · $166.05
- T+5 · 7d ago +2.60%α +3.19% · $169.14
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director George J. Morrow filed a Form 144 notice of intent to sell 14,700 shares of Neurocrine Biosciences common stock, with an approximate market value of $2.15 million based on the filing date. The shares are to be received upon exercise of stock options, and the sale is planned under a Rule 10b5-1 trading plan adopted on May 26, 2026.
Key Facts
- Director George J. Morrow filed Form 144 to sell 14,700 shares of Neurocrine Biosciences common stock.
- The approximate market value of the proposed sale is $2,147,670.
- Shares will be acquired upon exercise of stock options.
- The sale is planned under a Rule 10b5-1 trading plan adopted on May 26, 2026.
- The filing date is November 2, 2026.
- The proposed sale represents about 0.014% of Neurocrine's $14.9B market cap.
- A prior sale of 300 shares on October 30, 2026 is also noted in the filing.
Financial Impact
Proposed sale of 14,700 shares valued at approximately $2.15 million, representing a small fraction of the company's $14.9B market cap.
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur.
- Insider selling, even under a 10b5-1 plan, can be perceived negatively by the market if the volume is large relative to average trading.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010581 |
| Document: 0001950047-26-010581-index.html | 0001950047-26-010581 |
| Document: 0001950047-26-010581.txt | 0001950047-26-010581 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Viewing Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers